Ethiopia s total healthcare expenditure in ---- was ETB--.--bn (USD-.--bn), and this is expected to increase to ETB--.--bn (USD-.--bn) in ----. We forecast total expenditure to reach ETB--.--bn (USD-.--bn) by ----, equating to a five-year compound annual growth rate (CAGR) of -.- and -.- in local currency and US dollars respectively. ...This will improve steadily in line with economic development and improved living standards; however, this will happen at a very slow rate, reflecting the marginally greater per capita sales forecast of USD-- by ----. With around -- of the ---mn Ethiopian population living below the national poverty line and average per capita incomes at under half the current Sub-Saharan African average, lack of affordability is a considerable barrier to healthcare access in the East African country. The low affordability levels among the population demonstrate that subsidised healthcare is essential to achieving universal healthcare access in ...With around -- of the ---mn Ethiopian population living below the national poverty line and average per capita incomes at under half the current Sub-Saharan African average, lack of affordability is a considerable barrier to healthcare access in the East African country. The low affordability levels among the population demonstrate that subsidised healthcare is essential to achieving universal healthcare access in
...Ethiopia s pharmaceutical market is forecast to grow from ETB--.-bn (USD---mn) in ---- to ETB--.-bn (USD---mn) in ----. Over the medium-term, pharmaceutical expenditure is forecast to increase to ETB--.-bn (USD---mn) in ----, corresponding to a compound annual growth rate (CAGR) of -.- in local currency terms and -.- in US dollar terms. ...Highlighting this, blockbuster products including Seretide (salmeterol and fluticasonepropionate), Crestor (rosuvastatin) and Nexium (esomeprazole) are all registered in the country. Despite this, generic drugs will maintain an overriding share of the pharmaceutical market in Ethiopia, with low affordability levels and cost-containment efforts from the government supporting their uptake within the population. Pharmaceutical spending accounted for -.- of GDP and --.- of healthcare expenditure in ----. ...This will improve steadily in line with economic development and improved living standards; however, this will happen at a very slow rate, reflecting the marginally greater per capita sales forecast of USD- by ----.
...Ethiopia s government is actively facilitating investment into the sector and the country s economic growth trajectory over the coming years is very promising. This highlights the country s significant potential as an emerging pharmaceutical market. ...